

Freedom of Information Request

Reference Number: [EPUT.FOI.22.2454](#)

Date Received: [1 April 2022](#)

Information Requested:

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

- Afatinib
- Alectinib
- Atezolizumab monotherapy
- Atezolizumab in combination
- Bevacizumab
- Brigatinib
- Capmatenib
- Ceritinib
- Crizotinib
- Dacomitinib
- Dabrafenib with Trametinib
- Docetaxel monotherapy
- Durvalumab
- Erlotinib
- Gefitinib
- Gemcitabine
- Nintedanib with Docetaxel
- Nivolumab
- Osimertinib
- Paclitaxel

- Pembrolizumab monotherapy
 - Pembrolizumab in combination
 - Pemetrexed with Carboplatin/Cisplatin
 - Tepotinib
 - Vinorelbine with Cisplatin/Carboplatin
 - Any other SACT
 - Palliative care only
-

Response:

Essex Partnership University NHS Foundation Trust is a Mental Health, Learning Disability and Community Services Trust and does not offer these services.

Publication Scheme:

As part of the Freedom of Information Act all public organisations are required to proactively publish certain classes of information on a Publication Scheme. A publication scheme is a guide to the information that is held by the organisation. EPUT's Publication Scheme is located on its Website at the following link <https://eput.nhs.uk>